These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22925041)

  • 1. Targeting IL-1 in depression.
    Maes M; Song C; Yirmiya R
    Expert Opin Ther Targets; 2012 Nov; 16(11):1097-112. PubMed ID: 22925041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent regulation of depression-like behaviors through modulation of adrenergic receptor α₁A subtype expression revealed by the analysis of interleukin-1 receptor antagonist knockout mice.
    Wakabayashi C; Kiyama Y; Kunugi H; Manabe T; Iwakura Y
    Neuroscience; 2011 Sep; 192():475-84. PubMed ID: 21722710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide.
    Konsman JP; Veeneman J; Combe C; Poole S; Luheshi GN; Dantzer R
    Eur J Neurosci; 2008 Dec; 28(12):2499-510. PubMed ID: 19087175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression.
    Kubera M; Obuchowicz E; Goehler L; Brzeszcz J; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):744-59. PubMed ID: 20828592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males.
    Ovaskainen Y; Koponen H; Jokelainen J; Keinänen-Kiukaanniemi S; Kumpusalo E; Vanhala M
    Psychiatry Res; 2009 May; 167(1-2):73-9. PubMed ID: 19346005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression.
    Maes M
    Neuro Endocrinol Lett; 2008 Jun; 29(3):287-91. PubMed ID: 18580840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.
    Lamacchia C; Palmer G; Seemayer CA; Talabot-Ayer D; Gabay C
    Arthritis Rheum; 2010 Feb; 62(2):452-62. PubMed ID: 20112392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients.
    Maes M; Ruckoanich P; Chang YS; Mahanonda N; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):769-83. PubMed ID: 20561554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis.
    Volarevic V; Al-Qahtani A; Arsenijevic N; Pajovic S; Lukic ML
    Autoimmunity; 2010 Jun; 43(4):255-63. PubMed ID: 19845478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.
    Kubera M; Kenis G; Bosmans E; Zieba A; Dudek D; Nowak G; Maes M
    Pol J Pharmacol; 2000; 52(3):237-41. PubMed ID: 11055582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the course of brain inflammation on the endogenous IL-1beta/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette-Guérin in Lewis rats.
    Palin K; Verrier D; Tridon V; Hurst J; Perry VH; Dantzer R; Lestage J
    J Neuroimmunol; 2004 Apr; 149(1-2):22-30. PubMed ID: 15020061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation.
    Marijnissen RJ; Koenders MI; Smeets RL; Stappers MH; Nickerson-Nutter C; Joosten LA; Boots AM; van den Berg WB
    Arthritis Rheum; 2011 Oct; 63(10):2939-48. PubMed ID: 21618207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice.
    Koenders MI; Devesa I; Marijnissen RJ; Abdollahi-Roodsaz S; Boots AM; Walgreen B; di Padova FE; Nicklin MJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2008 Nov; 58(11):3461-70. PubMed ID: 18975337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes.
    Chizzolini C; Chicheportiche R; Burger D; Dayer JM
    Eur J Immunol; 1997 Jan; 27(1):171-7. PubMed ID: 9022014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced IL-1Ra/IL-1 ratio in ultraviolet B-exposed skin of patients with polymorphic light eruption.
    Janssens AS; Pavel S; Tensen CP; Teunissen MB; Out-Luiting JJ; Willemze R; de Gruijl FR
    Exp Dermatol; 2009 Mar; 18(3):212-7. PubMed ID: 19046297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
    Perrier S; Darakhshan F; Hajduch E
    FEBS Lett; 2006 Nov; 580(27):6289-94. PubMed ID: 17097645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo.
    Schmid AW; Lynch MA; Herron CE
    Hippocampus; 2009 Jul; 19(7):670-6. PubMed ID: 19115392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
    Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP
    Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.